1. Home
  2. PCRX vs BBNX Comparison

PCRX vs BBNX Comparison

Compare PCRX & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • BBNX
  • Stock Information
  • Founded
  • PCRX 2006
  • BBNX 2015
  • Country
  • PCRX United States
  • BBNX United States
  • Employees
  • PCRX N/A
  • BBNX N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • BBNX Medical/Dental Instruments
  • Sector
  • PCRX Health Care
  • BBNX Health Care
  • Exchange
  • PCRX Nasdaq
  • BBNX Nasdaq
  • Market Cap
  • PCRX 1.2B
  • BBNX 967.6M
  • IPO Year
  • PCRX 2011
  • BBNX 2025
  • Fundamental
  • Price
  • PCRX $23.63
  • BBNX $22.23
  • Analyst Decision
  • PCRX Buy
  • BBNX Strong Buy
  • Analyst Count
  • PCRX 5
  • BBNX 10
  • Target Price
  • PCRX $32.40
  • BBNX $26.10
  • AVG Volume (30 Days)
  • PCRX 532.5K
  • BBNX 1.1M
  • Earning Date
  • PCRX 11-05-2025
  • BBNX 11-06-2025
  • Dividend Yield
  • PCRX N/A
  • BBNX N/A
  • EPS Growth
  • PCRX N/A
  • BBNX N/A
  • EPS
  • PCRX N/A
  • BBNX N/A
  • Revenue
  • PCRX $705,848,000.00
  • BBNX $78,022,000.00
  • Revenue This Year
  • PCRX $7.36
  • BBNX $42.80
  • Revenue Next Year
  • PCRX $10.07
  • BBNX $34.58
  • P/E Ratio
  • PCRX N/A
  • BBNX N/A
  • Revenue Growth
  • PCRX 2.25
  • BBNX 550.45
  • 52 Week Low
  • PCRX $15.16
  • BBNX $8.89
  • 52 Week High
  • PCRX $27.64
  • BBNX $26.66
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 32.49
  • BBNX 56.62
  • Support Level
  • PCRX $24.31
  • BBNX $19.07
  • Resistance Level
  • PCRX $26.05
  • BBNX $23.08
  • Average True Range (ATR)
  • PCRX 0.76
  • BBNX 1.32
  • MACD
  • PCRX -0.33
  • BBNX -0.24
  • Stochastic Oscillator
  • PCRX 6.34
  • BBNX 70.86

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About BBNX Beta Bionics Inc. Common Stock

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.

Share on Social Networks: